Mounjaro was the drug that proved dual agonism worked. Before Tirzepatide was approved under the brand name Mounjaro for type 2 diabetes and Zepbound for obesity, the prevailing assumption was that targeting two receptors — GIP and GLP-1 — would not be meaningfully better than targeting one. The SURMOUNT clinical program proved otherwise, showing 18-20% average weight loss at 72 weeks. Retatrutide has now shown that three receptors are better than two. The question is how much the third receptor matters in practice.
The Mechanism Gap: Dual vs Triple
Mounjaro activates the GIP and GLP-1 receptors. Retatrutide activates those two plus the glucagon receptor. The GIP component in both drugs enhances insulin sensitivity and appears to reduce the nausea that pure GLP-1 activation causes — which is why Mounjaro users typically report better tolerability than Ozempic users at equivalent efficacy. The glucagon receptor in retatrutide adds increased energy expenditure through lipolysis and thermogenesis. Dr. Anil Jina, Eli Lilly’s VP of product development, has noted that the GIP component is the reason dual agonists achieve better tolerability. Retatrutide builds on that foundation with the third mechanism.
Weight Loss: SURMOUNT vs TRIUMPH
The SURMOUNT-1 trial showed 18-20% average weight loss at 72 weeks on the 15 mg tirzepatide dose. The TRIUMPH-4 trial showed 28.7% at 68 weeks on the 12 mg retatrutide dose. The gap of roughly 9-10 percentage points is the contribution of the glucagon receptor. In absolute pounds, a 250-pound person on Mounjaro loses 45-50 pounds. The same person on retatrutide loses 65-70 pounds. The TRIUMPH-1 subgroup data pushes that further: participants with a BMI of 35 or higher who stayed on retatrutide for 104 weeks lost an average of 85 pounds.
Practical Considerations
Mounjaro is FDA approved, available by prescription, and covered by many insurance plans for type 2 diabetes and weight loss. Retatrutide is not approved. Mounjaro’s manufacturing follows current Good Manufacturing Practices; every batch is tested for purity, potency, and sterility. Grey market retatrutide has none of these assurances. For anyone who responds adequately to Mounjaro, there is no compelling reason to switch. The additional weight loss from retatrutide is real, but is it worth the uncertainty of unapproved sourcing? That is a question only the individual can answer based on their specific circumstances and risk tolerance.
Leave a Reply